Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 June 2023.
Key highlights from this period include:
- Investigation and audit suggest production issue for PAT-DX1 was a one-off event
- Patrys commencing preparations for a replacement production run of PAT-DX1
- No toxicology or safety issues identified in draft reports from GLP toxicology studies
- US PTO grants two new patents for deoxymab technology providing coverage till 2039
The Company had a cash and short‑term investment balance of $4.0 million on 30 June 2023, with expected R&D rebate of $2.7 million.
Patrys CEO and MD, Dr James Campbell said:
“We are delighted that the investigation and audit by both the CDMO and our independent investigator have not identified any issue so far that is likely to impact on our future ability to manufacture GMP-grade PAT-DX1 for clinical trials…Based on the results to date, we believe we should be able to initiate a new production run in the coming months and have already commenced preparations for this.”